STOCK TITAN
  1. Home
  2. Sec-filings
  3. ACTU
  4. [Form 4] Actuate Therapeutics, Inc. Common stock Insider Trading Activity

[Form 4] Actuate Therapeutics, Inc. Common stock Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Positive)
Form Type
4
Rhea-AI Filing Summary

Citizens Financial Services Inc. (CZFS) has filed a Form 4 disclosing that director R. Joseph Landy executed a Code G transaction, gifting 20 shares of common stock on 30 June 2025 at a price of $0. Following the transaction, Landy’s direct ownership stands at 27,665.7745 shares. No derivative securities were involved, and the transfer represents an immaterial change (<0.1%) in his holdings, leaving overall insider ownership essentially unchanged.

Citizens Financial Services Inc. (CZFS) ha presentato un Modulo 4 che rivela che il direttore R. Joseph Landy ha effettuato una transazione di tipo Codice G, donando 20 azioni ordinarie il 30 giugno 2025 a un prezzo di $0. Dopo la transazione, la proprietà diretta di Landy ammonta a 27.665,7745 azioni. Non sono stati coinvolti titoli derivati, e il trasferimento rappresenta una variazione irrilevante (<0,1%) nelle sue partecipazioni, lasciando sostanzialmente invariata la proprietà interna complessiva.

Citizens Financial Services Inc. (CZFS) ha presentado un Formulario 4 que revela que el director R. Joseph Landy realizó una transacción de Código G, donando 20 acciones comunes el 30 de junio de 2025 a un precio de $0. Tras la transacción, la propiedad directa de Landy es de 27,665.7745 acciones. No se involucraron valores derivados y la transferencia representa un cambio insignificante (<0.1%) en sus participaciones, manteniendo prácticamente sin cambios la propiedad interna total.

Citizens Financial Services Inc. (CZFS)는 이사 R. Joseph Landy가 코드 G 거래를 실행하여 2025년 6월 30일에 보통주 20주를 가격 $0로 증여했음을 공개하는 양식 4를 제출했습니다. 거래 후 Landy의 직접 소유 주식 수는 27,665.7745주입니다. 파생 증권은 포함되지 않았으며, 이번 이전은 그의 보유 지분에서 미미한 변화(<0.1%)를 나타내어 전체 내부자 소유는 사실상 변함이 없습니다.

Citizens Financial Services Inc. (CZFS) a déposé un formulaire 4 révélant que le directeur R. Joseph Landy a effectué une transaction de Code G, en offrant 20 actions ordinaires le 30 juin 2025 au prix de 0 $. À la suite de la transaction, la détention directe de Landy s'élève à 27 665,7745 actions. Aucune valeur dérivée n'a été impliquée, et ce transfert représente un changement négligeable (<0,1 %) dans ses avoirs, laissant la propriété globale des initiés essentiellement inchangée.

Citizens Financial Services Inc. (CZFS) hat ein Formular 4 eingereicht, das offenlegt, dass der Direktor R. Joseph Landy eine Code G-Transaktion durchgeführt hat, bei der er am 30. Juni 2025 20 Stammaktien zu einem Preis von $0 verschenkte. Nach der Transaktion hält Landy direkt 27.665,7745 Aktien. Es waren keine derivativen Wertpapiere beteiligt, und die Übertragung stellt eine unwesentliche Änderung (<0,1%) seiner Beteiligungen dar, wodurch die Gesamtbesitzverhältnisse der Insider im Wesentlichen unverändert bleiben.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Director gifts 20 CZFS shares; negligible ownership change; neutral investor impact.

The transaction is coded “G,” confirming it is a bona-fide gift with no monetary consideration. The 20-share transfer is immaterial relative to the director’s remaining 27,665.7745 shares and to CZFS’s total float. Because there is no sale into the market and no shift in control, the filing does not alter insider sentiment or signal valuation concerns. Investors can view this as routine estate or charitable planning rather than a directional indicator.

Citizens Financial Services Inc. (CZFS) ha presentato un Modulo 4 che rivela che il direttore R. Joseph Landy ha effettuato una transazione di tipo Codice G, donando 20 azioni ordinarie il 30 giugno 2025 a un prezzo di $0. Dopo la transazione, la proprietà diretta di Landy ammonta a 27.665,7745 azioni. Non sono stati coinvolti titoli derivati, e il trasferimento rappresenta una variazione irrilevante (<0,1%) nelle sue partecipazioni, lasciando sostanzialmente invariata la proprietà interna complessiva.

Citizens Financial Services Inc. (CZFS) ha presentado un Formulario 4 que revela que el director R. Joseph Landy realizó una transacción de Código G, donando 20 acciones comunes el 30 de junio de 2025 a un precio de $0. Tras la transacción, la propiedad directa de Landy es de 27,665.7745 acciones. No se involucraron valores derivados y la transferencia representa un cambio insignificante (<0.1%) en sus participaciones, manteniendo prácticamente sin cambios la propiedad interna total.

Citizens Financial Services Inc. (CZFS)는 이사 R. Joseph Landy가 코드 G 거래를 실행하여 2025년 6월 30일에 보통주 20주를 가격 $0로 증여했음을 공개하는 양식 4를 제출했습니다. 거래 후 Landy의 직접 소유 주식 수는 27,665.7745주입니다. 파생 증권은 포함되지 않았으며, 이번 이전은 그의 보유 지분에서 미미한 변화(<0.1%)를 나타내어 전체 내부자 소유는 사실상 변함이 없습니다.

Citizens Financial Services Inc. (CZFS) a déposé un formulaire 4 révélant que le directeur R. Joseph Landy a effectué une transaction de Code G, en offrant 20 actions ordinaires le 30 juin 2025 au prix de 0 $. À la suite de la transaction, la détention directe de Landy s'élève à 27 665,7745 actions. Aucune valeur dérivée n'a été impliquée, et ce transfert représente un changement négligeable (<0,1 %) dans ses avoirs, laissant la propriété globale des initiés essentiellement inchangée.

Citizens Financial Services Inc. (CZFS) hat ein Formular 4 eingereicht, das offenlegt, dass der Direktor R. Joseph Landy eine Code G-Transaktion durchgeführt hat, bei der er am 30. Juni 2025 20 Stammaktien zu einem Preis von $0 verschenkte. Nach der Transaktion hält Landy direkt 27.665,7745 Aktien. Es waren keine derivativen Wertpapiere beteiligt, und die Übertragung stellt eine unwesentliche Änderung (<0,1%) seiner Beteiligungen dar, wodurch die Gesamtbesitzverhältnisse der Insider im Wesentlichen unverändert bleiben.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Kreis Leslie W.
(Last) (First) (Middle)
C/O BIOS EQUITY PARTNERS
1751 RIVER RUN SUITE 400
(Street)
FORT WORTH TX 76107
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
ACTUATE THERAPEUTICS, INC. [ ACTU ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director X 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/27/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
X Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/27/2025 P(1) 71,428 A $7 196,428 I Directly held by Bios 2024 Co-Invest, LP(3)(4)(5)
Common Stock 1,259,427 I Directly held by Bios Clinical Opportunity Fund, LP(3)(4)(5)
Common Stock 525,797 I Directly held by Bios Fund I, LP(3)(4)(5)
Common Stock 307,538 I Directly held by Bios Fund I QP, LP(3)(4)(5)
Common Stock 300,143 I Directly held by Bios Fund II, LP(3)(4)(5)
Common Stock 980,433 I Directly held by Bios Fund II QP, LP(3)(4)(5)
Common Stock 131,248 I Directly held by Bios Fund II NT, LP(3)(4)(5)
Common Stock 300,749 I Directly held by Bios Actuate Co-Invest I, LP(3)(4)(5)
Common Stock 383,791 I Directly held by Bios Fund III, LP(3)(4)(5)
Common Stock 2,506,667 I Directly held by Bios Fund III QP, LP(3)(4)(5)
Common Stock 404,814 I Directly held by Bios Fund III NT, LP(3)(4)(5)
Common Stock 2,094,650 I Directly held by Bios Actuate Co-Invest II, LP(3)(4)(5)
Common Stock 573,394 I Directly held by Bios Actuate Co-Invest III, LP(3)(4)(5)
Common Stock 84,917 I Directly held by BP Directors, LP(3)(4)(5)
Common Stock 60,973 I Directly held by Aaron G.L. Fletcher
Common Stock 8,056 I Directly held by KF Legacy Trust U/A/D December 7, 2016(6)
Common Stock 8,056 I Directly held by MF Legacy Trust U/A/D December 7, 2016(6)
Common Stock 69,375 I Directly held by Circle K Invesco, LP(7)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Warrant (Right to Buy) $7 06/27/2025 P(2) 71,428 (2) (2) Common Stock 71,428 $0 71,428 I Directly held by Bios 2024 Co-Invest, LP(3)(4)(5)
1. Name and Address of Reporting Person*
Kreis Leslie W.
(Last) (First) (Middle)
C/O BIOS EQUITY PARTNERS
1751 RIVER RUN SUITE 400
(Street)
FORT WORTH TX 76107
(City) (State) (Zip)
Relationship of Reporting Person(s) to Issuer
X Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
Cavu Advisors, LLC
(Last) (First) (Middle)
C/O BIOS EQUITY PARTNERS
1751 RIVER RUN SUITE 400
(Street)
FORT WORTH TX 76107
(City) (State) (Zip)
Relationship of Reporting Person(s) to Issuer
X Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
Cavu Management, LP
(Last) (First) (Middle)
C/O BIOS EQUITY PARTNERS
1751 RIVER RUN SUITE 400
(Street)
FORT WORTH TX 76107
(City) (State) (Zip)
Relationship of Reporting Person(s) to Issuer
X Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
BIOS Fund I, LP
(Last) (First) (Middle)
C/O BIOS EQUITY PARTNERS
1751 RIVER RUN SUITE 400
(Street)
FORT WORTH TX 76107
(City) (State) (Zip)
Relationship of Reporting Person(s) to Issuer
X Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
BIOS Fund I QP, LP
(Last) (First) (Middle)
C/O BIOS EQUITY PARTNERS
1751 RIVER RUN SUITE 400
(Street)
FORT WORTH TX 76107
(City) (State) (Zip)
Relationship of Reporting Person(s) to Issuer
X Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
Bios Equity Partners, LP
(Last) (First) (Middle)
C/O BIOS EQUITY PARTNERS
1751 RIVER RUN SUITE 400
(Street)
FORT WORTH TX 76107
(City) (State) (Zip)
Relationship of Reporting Person(s) to Issuer
X Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
BIOS Fund II, LP
(Last) (First) (Middle)
C/O BIOS EQUITY PARTNERS
1751 RIVER RUN SUITE 400
(Street)
FORT WORTH TX 76107
(City) (State) (Zip)
Relationship of Reporting Person(s) to Issuer
X Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
BIOS Fund II NT, LP
(Last) (First) (Middle)
C/O BIOS EQUITY PARTNERS
1751 RIVER RUN SUITE 400
(Street)
FORT WORTH TX 76107
(City) (State) (Zip)
Relationship of Reporting Person(s) to Issuer
X Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
BIOS Fund II QP, LP
(Last) (First) (Middle)
C/O BIOS EQUITY PARTNERS
1751 RIVER RUN SUITE 400
(Street)
FORT WORTH TX 76107
(City) (State) (Zip)
Relationship of Reporting Person(s) to Issuer
X Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
Bios Equity Partners II, LP
(Last) (First) (Middle)
C/O BIOS EQUITY PARTNERS
1751 RIVER RUN SUITE 400
(Street)
FORT WORTH TX 76107
(City) (State) (Zip)
Relationship of Reporting Person(s) to Issuer
X Director X 10% Owner
Officer (give title below) Other (specify below)
Explanation of Responses:
1. Pursuant to a Securities Purchase Agreement (the "Securities Purchase Agreement"), dated as of June 25, 2025, between Actuate Therapeutics, Inc. (the "Issuer") and certain institutional and accredited investors, Bios 2024 Co-Invest, LP ("Bios 2024 Co-Invest") purchased from the Issuer in a private placement 71,428 shares of common stock, par value $0.000001 per share (the "Common Stock"), and warrants to purchase 71,428 shares of Common Stock (the "Warrants"). The closing of the transactions contemplated by the Securities Purchase Agreement occurred on June 27, 2025.
2. The Warrants are exercisable on a cash only basis at any time after the date of issuance and expire 20 days following the earliest to occur of (i) the U.S. Food and Drug Administration ("FDA") issuing Breakthrough Therapy designation for elraglusib and (ii) the date that the FDA provides written communication available to the Issuer of its determination as to whether the Issuer may pursue registration for elraglusib using Phase 2 or Phase 3 clinical data.
3. Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I"), Bios Fund I QP, LP ("Bios Fund I QP") and BP Directors, LP ("BP Directors"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Actuate Co-Invest I, LP ("Bios Actuate Co-Invest I"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP"), Bios Fund III NT, LP ("Bios Fund III NT"), Bios Actuate Co-Invest II, LP ("Bios Actuate Co-Invest II") and Bios Actuate Co-Invest III, LP ("Bios Actuate Co-Invest III"). Bios Equity COF, LP ("Bios Equity COF") is the general partner of Bios Clinical Opportunity Fund, LP ("Bios COF") and Bios 2024 Co-Invest.
4. (Footnote 3 Continue) Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP.
5. (Footnote 3 Continue)The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively.
6. Shares are held in a trust, which has an independent trustee, for the benefit of Mr. Fletcher's children. Mr. Fletcher disclaims beneficial ownership of such shares other than to the extent he may have a pecuniary interest therein.
7. Shares are held by Circle K Invesco, LP, over which Mr. Kreis has sole voting and investment control.
Remarks:
Exhibit 24 - Power of Attorney Each of the reporting persons may be deemed a "director by deputization" as the result of Aaron G.L. Fletcher's position as a director of the Issuer. This Form 4 is the second of three Forms 4 filed relating to the same event. The Form 4 has been split into three filings because there are more than 10 reporting persons in total, and the SEC's EDGAR filing system limits a single Form 4 to a maximum of 10 reporting persons. The first Form 4 was filed by Aaron G.L. Fletcher as the designated filer. The third Form 4 will be filed by Bios Equity COF, LP as the designated filer.
Leslie W. Kreis, Jr By: /s/ John Fucci, as attorney-in-fact 06/30/2025
Cavu Advisors, LLC By: /s/ John Fucci, as attorney-in-fact 06/30/2025
Cavu Management, LP By: Cavu Advisors, LLC, its general partner By: /s/ John Fucci, as attorney-in-fact 06/30/2025
Bios Fund I, LP By: Bios Equity Partners, LP, its general partner By: Cavu Management, LP, its general partner By: Cavu Advisors, LLC, its general partner By: /s/ John Fucci, as attorney-in-fact 06/30/2025
Bios Fund I QP, LP By: Bios Equity Partners, LP, its general partner By: Cavu Management, LP, its general partner By: Cavu Advisors, LLC, its general partner By: /s/ John Fucci, as attorney-in-fact 06/30/2025
Bios Equity Partners, LP By: Cavu Management, LP, its general partner By: Cavu Advisors, LLC, its general partner By: /s/ John Fucci, as attorney-in-fact 06/30/2025
Bios Fund II, LP By: Bios Equity Partners II, LP, its general partner By: Cavu Management, LP, its general partner By: Cavu Advisors, LLC, its general partner By: /s/ John Fucci, as attorney-in-fact 06/30/2025
Bios Fund II NT, LP By: Bios Equity Partners II, LP, its general partner By: Cavu Management, LP, its general partner By: Cavu Advisors, LLC, its general partner By: /s/ John Fucci, as attorney-in-fact 06/30/2025
Bios Fund II QP, LP By: Bios Equity Partners II, LP, its general partner By: Cavu Management, LP, its general partner By: Cavu Advisors, LLC, its general partner By: /s/ John Fucci, as attorney-in-fact 06/30/2025
Bios Equity Partners II, LP By: Cavu Management, LP, its general partner By: Cavu Advisors, LLC, its general partner By: /s/ John Fucci, as attorney-in-fact 06/30/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

Who filed the Form 4 for CZFS?

R. Joseph Landy, a director of Citizens Financial Services Inc., filed the Form 4.

What type of transaction does Code G represent?

Code G indicates a gift transaction with no monetary consideration.

How many CZFS shares were involved in the transaction?

The filing reports a gift of 20 common shares.

What is Landy’s total share ownership after the gift?

He directly owns 27,665.7745 CZFS shares following the reported transaction.

Are any derivative securities reported in this Form 4?

No, the filing shows no derivative securities acquired or disposed of.
Stock ACTU logo
Actuate Therapeutics Inc

NASDAQ:ACTU

ACTU Rankings

#6132 Ranked by Market Cap
N/A Ranked by Dividends

ACTU Latest News

Jun 24, 2025
Actuate Therapeutics Highlights Significant and Sustained Survival Benefit in Key Metastatic Pancreatic Cancer Patient Populations in Phase 2 Elraglusib Trial
Jun 20, 2025
Actuate Therapeutics Reports Positive Biomarker and Machine Learning Data from Phase 2 Elraglusib Trial in First-Line Treatment of Metastatic Pancreatic Cancer at ASCO
Jun 16, 2025
Actuate Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes
Jun 2, 2025
Actuate Therapeutics Shares Highlights from KOL Event on Positive Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer
May 31, 2025
Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment of Metastatic Pancreatic Cancer

ACTU Latest SEC Filings

Jun 30, 2025
[Form 4] Actuate Therapeutics, Inc. Common stock Insider Trading Activity
Jun 30, 2025
[Form 4] Actuate Therapeutics, Inc. Common stock Insider Trading Activity
Jun 30, 2025
[SCHEDULE 13D/A] Actuate Therapeutics, Inc. Common stock SEC Filing
Jun 26, 2025
[8-K] Actuate Therapeutics, Inc. Common stock Reports Material Event

ACTU Stock Data

114.19M
15.86M
18.69%
51.79%
0.4%
Biotechnology
Pharmaceutical Preparations
Link
United States
FORT WORTH